Patents Assigned to Amersham Health AS
-
Publication number: 20070212305Abstract: The invention provides contrast agents for optical imaging of lung cancer in patients. The contrast agents may be used in diagnosis of lung cancer, for follow up of progress in disease development, for follow up of treatment of lung cancer and for surgical guidance. Further, the invention provides methods for optical imaging of lung cancer in patients.Type: ApplicationFiled: December 17, 2004Publication date: September 13, 2007Applicant: AMERSHAM HEALTH ASInventors: Jo Klaveness, Edvin Johannesen, Helge Tolleshaug
-
Patent number: 7102354Abstract: The present invention relates to devices and method for melting solid polarised sample while retaining a high level of polarisation. In an embodiment of the present invention a sample is polarised in a sample-retaining cup 9 in a strong magnetic field in a polarising means 3a, 3b, 3c in a cryostat 2 and then melted inside the cryostat 2 by melting means such as a laser 8 connected by an optical fibre 4 to the interior of the cryostat.Type: GrantFiled: February 22, 2005Date of Patent: September 5, 2006Assignee: Amersham Health ASInventors: Jan Henrik Ardenkjaer-Larsen, Oskar H. E. Axelsson, Klaes Koppel Golman, Jan Wolber, Mark Howard
-
Patent number: 7082326Abstract: A method of magnetic resonance (MR) imaging of blood perfusion in vascularized organs of interest, e.g. the myocardium, the kidneys, the brain, the liver wherein a contrast agent composition comprising a particulate superparamagnetic metal oxide is administered.Type: GrantFiled: September 27, 2002Date of Patent: July 25, 2006Assignee: Amersham Health ASInventor: Lars Johansson
-
Patent number: 7060731Abstract: This application relates to the use of certain amines of formula (I) for combatting and preventing systemic and local complement activation, and in particular to the use of meglumine and derivatives and optionally salts thereof in combatting and preventing said activation. The amines are also of use in combatting activation of the kinin/kallikrein system or blood coagulation system.Type: GrantFiled: September 12, 2002Date of Patent: June 13, 2006Assignee: Amersham Health ASInventors: Anne Juelsrud, Gunn Ragnhild Hoigaard Bjerke
-
Patent number: 7014839Abstract: The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.Type: GrantFiled: November 1, 2002Date of Patent: March 21, 2006Assignee: Amersham Health ASInventors: Jo Klaveness, Bjorn Fuglaas, Pål Rongved, Edvin Johannesen, Paul Mark Henrichs, Wolfgang Hans Heinrich Gunther, Edward Richard Bacon, John Luke Toner, Gregory Lynn McIntire, Vinay C. Desai
-
Patent number: 6974882Abstract: A process for the preparation of iodixanol by dimerization of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide (“Compound A”) in which, after the dimerization step, unreacted Compound A is precipitated from the reaction mixture and recovered for re-use. The process substantially increases the net yield of iodixanol and simplifies its purification.Type: GrantFiled: August 6, 2001Date of Patent: December 13, 2005Assignee: Amersham Health ASInventor: Ole Magne Homestad
-
Patent number: 6962803Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.Type: GrantFiled: October 22, 2003Date of Patent: November 8, 2005Assignee: Amersham Health ASInventors: Henry Wolfe, Fahar Merchant, Rosemina Merchant, Christopher Black, Harry Storflor, Geir Stokke, Halldis Hellebust
-
Publication number: 20050234337Abstract: Administration by injection or infusion to patients of an injectable liquid for diagnostic or therapeutic purposes is provided by a syringe adapter connectable with an automatic syringe pump and a syringe containing contents to be dispensed. The syringe adapter includes an adapter body receivable by the syringe pump, a syringe retainer for retaining the syringe, and a syringe driver for agitating the contents of the syringe. More particularly the invention relates to an adapter connectable with a syringe pump and methods for delivery of an injectable liquid using such adapter. By connecting an adapter according to the invention to a syringe and a syringe pump, rotation of the syringe is achieved and homogeneity of the injectable is preserved. Particularly, the injectable liquid is an ultrasound contrast agent comprising an aqueous dispersion of gas-filled microbubbles or of particulate matter.Type: ApplicationFiled: August 7, 2003Publication date: October 20, 2005Applicant: Amersham Health ASInventor: Martin Browne
-
Patent number: 6926189Abstract: An apparatus for welding closed one end of each of a multiplicity of open-ended tubes suitable for use as brachytherapy capsules includes a welding station having a welding position for welding closed one end of a tube, a rotatable platform having an outside edge, a tube holder positioned adjacent the outside edge, the tube holder movable between a loading position and the welding position, and a feed line positioned in overlying registry with the tube holder at the loading position.Type: GrantFiled: October 22, 2002Date of Patent: August 9, 2005Assignee: Amersham Health ASInventors: Charles Shanks, Kevin Helle, John Krewer, Robert Hallgren
-
Patent number: 6921525Abstract: The invention provides a composition of matter of the formula (I): V-L-R where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic angiotensin derivative or analog then V-L-R is other than a non-metal radionuclide substituted peptide (e.g. 125I substituted angiotensin II) and L-V is other than simply a peptide with a chelating agent amide bonded to a side chain thereof. This composition of matter may be used to image cardiovascular diseases and disorders.Type: GrantFiled: February 21, 2003Date of Patent: July 26, 2005Assignee: Amersham Health ASInventors: Jo Klaveness, Anne Naevestad, Alan Cuthbertson
-
Patent number: 6906171Abstract: The synthesis of peptides comprising disulphide bridges is challenging since it is difficult to ensure that the correct cysteine residues combine to form the desired disulphide bridges. The present invention describes novel protection techniques useful in the preparation of peptides. Described is a process for the deprotection of an Acm-, MBzl- and/or tBu-protected thiol which comprises reacting said protected thiol with an acid in the presence of an oxidising agent at a temperature sufficient to effect deprotection and generation of disulphide bonds.Type: GrantFiled: January 18, 2002Date of Patent: June 14, 2005Assignee: Amersham Health ASInventor: Alan Cuthbertson
-
Patent number: 6901281Abstract: The invention provides a method of magnetic resonance imaging of regional blood oxygenation which comprises administering into the vasculature of a vascularized human or non-human animal subject a T2 blood pool contrast agent, detecting a magnetic resonance signal from at least part of the vasculature of said subject into which said contrast agent distributes, and manipulating said signal to generate an indication of the partial pressure of oxygen (pO2) in at least part of said vasculature.Type: GrantFiled: March 22, 2001Date of Patent: May 31, 2005Assignee: Amersham Health ASInventors: Atle Bjørnerud, Kenneth Edmund Kellar, Karen Briley-Saebo, Lars Johansson
-
Patent number: 6875420Abstract: Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or “microbubbles,” comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of microbubbles comprised of the gas.Type: GrantFiled: July 18, 1997Date of Patent: April 5, 2005Assignee: Amersham Health ASInventor: Steven C. Quay
-
Patent number: 6872380Abstract: The present invention provides a process for the preparation of an MR contrast agent, said process comprising: i) obtaining a solution in a solvent of a hydrogenatable, unsaturated substrate compound and a catalyst for the hydrogenation of said substrate compound; ii) introducing said solution in droplet form into a chamber containing hydrogen gas (H2) enriched in para-hydrogen (p-1H2) and/or ortho-deuterium (o-2H2) whereby to hydrogenate said substrate to form a hydrogenated imaging agent; iii) optionally subjecting said hydrogenated imaging agent to a magnetic field having a field strength below earth's ambient field strength; iv) optionally dissolving said imaging agent in an aqueous medium; v) optionally separating said catalyst from the solution of said imaging agent in said aqueous medium; vi) optionally separating said solvent from the solution of said imaging agent in said aqueous medium; and vii) optionally freezing the solution of said imaging agent in said aqueous medium.Type: GrantFiled: November 16, 2001Date of Patent: March 29, 2005Assignee: Amersham Health ASInventors: Oskar Axelsson, Charlotte Olofsson, Axel Morgenstjerne, Georg Hansson, Haukur Johannesson, Jan-Henrik Ardenkjaer-Larsen
-
Publication number: 20050002865Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.Type: ApplicationFiled: December 15, 2003Publication date: January 6, 2005Applicant: Amersham Health ASInventors: Jo Klaveness, Pal Rongved, Anders Hogset, Helge Tolleshaug, Alan Cuthbertson, Aslak Godal, Lars Hoff, Geir Gogstad, Klaus Bryn, Anne Naevestad, Dagfinn Lovhaug, Halldis Hellebust, Magne Solbakken
-
Patent number: 6811766Abstract: A combined preparation comprising: i) an ultrasound contrast agent capable of accumulation in tissue microvasculature; and ii) a pharamacologically effective amount of a vasodilator drug may be used in perfusion imaging, especially of the myocardium. The contrast agent accumulates in tissue in concentrations related to the regional rate of tissue perfusion, and the vasodilator drug enhances distinction between normally perfused and underperfused tissue.Type: GrantFiled: April 20, 2000Date of Patent: November 2, 2004Assignee: Amersham Health ASInventors: Morten Eriksen, Jonny Østensen, Sigmund Frigstad, Pål Rongved
-
Patent number: 6806045Abstract: A method for the identification and characterization of a receptor in target tissue for which a selected vector has affinity, wherein a transfected cell line expressing the receptor is added to a suspension of encapsulated microbubbles to which the selected vector is coupled and allowing the microbubbles and cells coupled thereto to float to the surface of the suspension. Upon isolating the microbubble-bound cells at the surface, these may be cultured to study the receptor, or cells may be lysed, amplifying the receptor-encoding cDNA and sequencing the cDNA.Type: GrantFiled: January 18, 2002Date of Patent: October 19, 2004Assignee: Amersham Health ASInventors: Mari Ann Kulseth, Dagfinn Lovhaug, Aslak Godal
-
Patent number: 6783752Abstract: Ultrasonic visualisation of a suject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations include a coadministerable composition comprising a diffusible component capable of inward diffusion into the dispersed gas phase to promote temporary growth thereof. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences in return signal intensity from normal and hypoperfused myocardial tissue respectively.Type: GrantFiled: December 5, 2001Date of Patent: August 31, 2004Assignee: Amersham Health ASInventors: Jonny Østensen, Morten Eriksen, Sigmund Frigstad, Pål Rongved
-
Publication number: 20040131548Abstract: The present invention provides contrast agents for use in diagnostic ultrasound studies comprising microbubbles of gas or a gas precursor encapsulated by non-proteinaceous crosslinked or polymerised amphiphilic moieties.Type: ApplicationFiled: May 29, 2003Publication date: July 8, 2004Applicant: Amersham Health ASInventors: Jo Klaveness, Hanno Priebe, Pal Rongved, Lars Stubberud
-
Patent number: RE38856Abstract: The invention provides a process by which ultra low salt content triiodinated aromatic compounds may be isolated from a highly acidic hot triiodination raction reaction medium in a straightforward fashion. The process involves increasing the pH to above 5 a value in the range of 3 to 7 with sodium hydroxide, addition of sodium bisulphite and/or sodium dithionite, addition of seed crystals, cooling slowly, and washing the collected precipitate with water.Type: GrantFiled: October 24, 2002Date of Patent: October 25, 2005Assignee: Amersham Health ASInventors: William Thielking, Einar Odd Ingvoldstad, Trygve Gulbrandsen